2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.114 (Poster) Outcomes of Patients Diagnosed with Lung Cancer after COVID 19 Infection

Pdf Summary

A retrospective study was conducted to evaluate the outcomes of lung cancer patients who were diagnosed with COVID-19. The study included patients who were diagnosed with lung cancer within six months of their COVID-19 diagnosis. The primary endpoint was overall survival, defined as the time from lung cancer diagnosis to death. The secondary endpoint was progression-free survival, defined as the time from lung cancer diagnosis to progression or death.<br /><br />The study found that the mean age of the patients was 70 years, with 62% females and 38% males. The majority of the patients were Caucasians (65%) and African Americans (23%). The mean smoking pack years was 42.7 years, and 16.3% of patients were never smokers. Among patients with non-small cell lung cancer (NSCLC), 38% had stage I-II, 29.8% had stage III, and 31.6% had stage IV. For patients with squamous cell NSCLC, they were evenly distributed across all stages. Most patients with small cell lung cancer (SCLC) were at stage IV (71.4%).<br /><br />The treatments received by the patients included surgery (33.7%), radiation (26.7%), chemotherapy (41.9%), immunotherapy (23.3%), and targeted therapy (4.7%). Additionally, 14% of the patients received a second line treatment.<br /><br />The study concluded that patients diagnosed with lung cancer after COVID-19 infection were able to receive standard of care treatments, and their outcomes were consistent with their expected stage-adjusted survival. The study suggests that the higher incidence of lung cancer among COVID-19 patients may be attributed to increased imaging performed in the setting of COVID-19 infection. The findings of this study provide insights into the outcomes of lung cancer patients who develop COVID-19 and can help guide treatment decisions for this population.

Asset Subtitle

Zaid Al Saheli

Keywords

retrospective study

lung cancer

COVID-19

overall survival

progression-free survival

age

gender

cancer stage

treatments

incidence